Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.

Pharmacogenomics - 1 May 2013

Gschwind Liliane, Rollason Victoria, Boehlen Françoise, Rebsamen Michela, Combescure Christophe, Grünenwald Michèle, Matthey Alain, Bonnabry Pascal, Dayer Pierre, Desmeules Jules Alexandre

Abstract excerpt

AIM: The objective of this study was to investigate the impact of CYP2C9 polymorphisms and drug-drug interactions on the risk of overanticoagulation in patients treated with acenocoumarol, a vitamin K antagonist. MATERIALS & METHODS: A prospective observational study was performed on patients starting acenocoumarol (n = 115). CYP2C9 genotypes were assessed. Data on International Normalized Ratio, comedications...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acenocoumarol
Share to Anticoagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aryl Hydrocarbon Hydroxylases

Share to Blood Coagulation

Share to Blood Coagulation Disorders

Share to Cytochrome P-450 CYP2C9

Share to Drug Interactions

Share to International Normalized Ratio

Source

Identifiers

PMID: 23651023
DOI: 10.2217/pgs.13.55

Genes

CYP2C9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.PMID 23651023Read ↗

Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users.Semantic proximity Read ↗

VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.Semantic proximity Read ↗

Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.Semantic proximity Read ↗

Acenocoumarol stabilization is delayed in CYP2C93 carriers.Semantic proximity Read ↗

Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period.Semantic proximity Read ↗

Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment.Semantic proximity Read ↗

CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary.Semantic proximity Read ↗

Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.Semantic proximity Read ↗

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.Semantic proximity Read ↗

An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol.Semantic proximity Read ↗

Pharmacogenetics of acenocoumarol pharmacodynamics.Semantic proximity Read ↗

Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.